Citizens JMP raised the firm’s price target on Aquestive Therapeutics (AQST) to $12 from $9 and keeps an Outperform rating on the shares. Aquestive announced the issuance of two additional patents for Anaphylm, extending brand exclusivity through at least 2037, the analyst tells investors in a research note. The patents are meaningfully value accretive as they cover compositions of matter for the novel epinephrine prodrug used in the product candidate, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm
- Aquestive Therapeutics Advances Anaphylm Clinical Development
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Aquestive Therapeutics Highlights at Global Investor Conference